Synonym
KW 2170; KW2170; KW-2170
IUPAC/Chemical Name
6H-Pyrazolo(4,5,1-de)acridin-6-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(((2-hydroxyethyl)amino)methyl)-, dihydrochloride
InChi Key
VPJUIFWAPQSXSP-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H23N5O4.2ClH/c21-6-1-7-23-12-3-2-11-13(10-22-8-9-26)24-25-18(11)16(12)20(29)17-14(27)4-5-15(28)19(17)25;;/h2-5,22-23,26-28H,1,6-10,21H2;2*1H
SMILES Code
O=C1C2=C(C(O)=CC=C2O)N(N=C3CNCCO)C4=C3C=CC(NCCCN)=C14.[H]Cl.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
470.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ashizawa T, Shimizu M, Gomi K, Okabe M. Antitumor activity of KW-2170, a novel pyrazoloacridone derivative. Anticancer Drugs. 1998 Mar;9(3):263-71. doi: 10.1097/00001813-199803000-00009. PMID: 9625437.
2: Saeki T, Eguchi K, Takashima S, Sugiura T, Hida T, Horikoshi N, Aiba K, Kuwabara T, Ogawa M. Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumors. Cancer Chemother Pharmacol. 2004 Nov;54(5):459-68. doi: 10.1007/s00280-004-0808-z. PMID: 15290094.
3: Kuramitsu T, Takai K, Ohashi R, Kuwabara T. Determination of the anticancer drug KW-2170, a pyrazoloacridone derivative, and its metabolites in human and dog plasma by high-performance liquid chromatography using an electrochemical detector. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):231-7. doi: 10.1016/s1570-0232(01)00580-3. PMID: 11888050.
4: Verschraegen CF. KW-2170 (Kyowa Hakko Kogyo). IDrugs. 2002 Oct;5(10):1000-3. PMID: 12800063.
5: De Souza PL, North S, Bolger GB, Spiridonidis H, Lim R, Khoo KS, Phillips J, Fujimori M. A phase II trial of weekly i.v. KW-2170 in advanced castrate- resistant prostate cancer. Asia Pac J Clin Oncol. 2010 Dec;6(4):292-7. doi: 10.1111/j.1743-7563.2010.01328.x. Epub 2010 Nov 3. PMID: 21114779.
6: Estes JM, Leath CA, Williams S, Modiano MR, Sawyer M, Cohn D, Straughn JM, Barnes MN, Alvarez RD. Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer. Gynecol Oncol. 2006 Aug;102(2):338-42. doi: 10.1016/j.ygyno.2005.12.031. Epub 2006 Feb 20. PMID: 16487997.
